Glycomine

Glycomine is a clinical-stage biotechnology company developing new therapies for rare genetic diseases. Their lead candidate, GLM101, is a replacement therapy for PMM2-CDG, the most prevalent form of congenital diseases of glycosylation (CDG). The company is currently preparing to advance in clinical proof-of-concept studies.